Analyst downgrades Merck shares on concerns over 1 drug's delay, study that could hurt another

  • by: LINDA A. JOHNSON , Associated Press
  • Updated: February 4, 2013 - 3:52 PM

TRENTON, N.J. - Shares of drugmaker Merck & Co. declined Monday after two analysts downgraded their ratings, mainly due to worries that results of patient studies could hurt prospects for a few drugs and drag down future revenue and profit.

ADVERTISEMENT

Connect with twitterConnect with facebookConnect with Google+Connect with PinterestConnect with PinterestConnect with RssfeedConnect with email newsletters

ADVERTISEMENT

Advertisement
Golden Gavel by Star Tribune

Countdown to great deals

Bid Sept. 21-29

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT